Table 1.
Baseline Characteristics of Patients with Type 2 Diabetes by New Users of SGLT2 Inhibitor and Other 2nd Line Therapies, MarketScan Databasesa
| SGLT2 Inhibitor New Users (n=53,691) | Matched Other 2nd Line Therapy New Users (n=259,705) | |
|---|---|---|
|
|
||
| Age, years | 52.9±9.5 | 52.9±9.6 |
| Female sex | 46.6 | 47.2 |
| 2nd line diabetes therapy b | ||
| Canagliflozin | 37.9 | -- |
| Dapagliflozin | 29.6 | -- |
| Empagliflozin | 32.0 | -- |
| Ertugliflozin | 0.5 | -- |
| Sulfonylurea | -- | 45.2 |
| DPP-4 inhibitors | -- | 18.9 |
| GLP-1 receptor agonist | -- | 14.7 |
| Thiazolidinediones | -- | 4.3 |
| Insulin | -- | 16.9 |
| Comorbidities | ||
| Hypertension | 65.2 | 61.9 |
| Kidney disease | 1.8 | 3.1 |
| Chronic pulmonary disease | 2.9 | 3.5 |
| Depression | 7.7 | 8.3 |
| Metastatic cancer | 0.3 | 0.6 |
| Asthma | 2.9 | 3.0 |
| Other medications | ||
| ACE inhibitors | 41.9 | 42.9 |
| Angiotensin receptor blockers | 26.3 | 22.5 |
| Alpha-blockers | 0.5 | 0.7 |
| Beta-blockers | 23.5 | 23.7 |
| Calcium channel blockers | 20.0 | 20.3 |
| Loop diuretics | 5.5 | 6.1 |
| Potassium-sparing diuretics | 5.2 | 5.3 |
| Thiazide diuretics | 12.9 | 13.3 |
| Direct vasodilators | 2.8 | 2.9 |
a
Data are expressed as mean±SD or %.
b
First 2nd line therapy patients were prescribed.
Abbreviations: SGLT2 = sodium-glucose cotransporter-2; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; ACE = angiotensin-converting enzyme